Proceeds to support the clinical development of Atea’s oral, direct acting antiviral medicine for COVID-19, in addition to advancing its diverse pipeline of treatments for viral diseasesInvestigational new drug application cleared by U.S. Food and Drug Administration to start Phase 2 study of AT-527, Atea’s oral purine nucleotide prodrug for patients hospitalized with moderate COVID-19       BOSTON, May 20, 2020 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced a $215 million Series D financing. The financing was led by Bain Capital Life Sciences and also included new investors RA Capital Management, Perceptive Advisors, Rock Springs Capital, Adage Capital Management, funds and accounts managed by T. Rowe Price Associates,

Read More At Article Source | Article Attribution